Omgeo and Eze Automate Matching Between Platforms

manhattan-14
Both companies have presences in New York.

Written in the XML messaging format, the new link allows for enhanced straight-through processing between the two platforms, allowing buy-side firms to match exchange-traded derivatives (ETD), equity and fixed income trades with brokers.

"Futures and listed options have become integral parts of buy-side trading strategies, and firms need to ensure their trade processing capabilities can keep up," says Ted Leveroni, executive director of derivative strategy and external relations at Omgeo. "This link will help users eliminate unnecessary risk while improving efficiencies across the trade lifecycle, with equities, fixed income and ETD trades processed from a single platform."

The Eze Software Group was formed after agency broker ConvergEx sold its RealTick and Eze Castle Software businesses to private equity firm TPG Capital.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Banks seemingly build more than buy, but why?

Waters Wrap: A new report states that banks are increasingly enticed by the idea of building systems in-house, versus being locked into a long-term vendor contract. Anthony explores the reason for this shift.

Pushing the boundaries of TCA

S&P Global Market Intelligence finished runner-up in the perennially competitive TCA system provider category of the Waters Rankings 2024. Michael Richter, global head of trading analytics, discusses the TCA challenges facing the firm’s buy- and sell…

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here